[Various aspects of rehabilitation of patients with myocardial infarct at the hospital stage]. / Nekotorye aspekty reabilitatsii bol'nykh infarktom miokarda na gospital'nom étape.

The paper presents the results of accelerated physical rehabilitation in 1449 patients with large-focal myocardial infarction. Gradual expansion of movement regimen was based on a programme comprising 7 hospital stages for three clinical groups of patients; those with mild (I), medium (II) and severe (III) course of the disease. Rehabilitation procedures were to take up 35-40 days in Group I, 40-45 days in Group II, and 50 and more days in Group III. The control group was composed of 220 patients on conventional treatment with prolonged bed rest. Accelerated rehabilitation was successful in 78.2% of the patients from Group I and II. The study-group patients showed reduced incidence of recurrent acute coronary insufficiency, relapses of myocardial infarction, thromboembolism, late cardiorrhexis, as compared to the controls. The duration of hospital stay was reduced by 23.1 days. Mortality (after 3-5 days of acute condition) dropped from 8.9% to 5.2%. Exercise tolerance was three times as great, as compared to that of the controls.

[Effectiveness and the methods of using streptokinase in myocardial infarct and preinfarct stenocardia]. / Effektivnost' i metodika primeneniia streptokinazy u bol'nykh infarktom miokarda i predynfarktnoi stenokardiei.

The effectiveness of streptokinase treatment of patients with myocardial infarction as compared to the control group and patients given anticoagulants is analysed. It is shown that the frequency of recurrent myocardial infarctions, congestive circulatory insufficiency, shock, and thromboembolic complications is lower in the group of patients treated with streptokinase than in the control group. Streptokinase improves the course of the disease and the prognosis in patients with preinfarction angina pectoris. The effect of streptokinase is higher in the first 3--6 hours after the development of myocardial infarction and in individuals under the age of 65. The effectiveness of the treatment does not diminish when the drug is injected for a short time and in small doses (300,000--750,000 U).